July 17, 2025 | Aclymate, Carbon Emissions, Carbon footprint, Hybrid Events, Hybrid meetings, Impetus Digital, Pharma meetings, Sustainability, carbon neutral, green pharma, pharma vvents, reduce carbon, sustainable pharma
Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

A year after Impetus Digital first calculated and offset all of our home office-related emissions, we’re excited to announce that we have now implemented Phase 2 of our journey toward carbon neutrality. As of January 2024, all of the carbon emissions associated with Impetus Digital staff attending hybrid meetings live (i.e., flights, ground transportation for local meetings, and accommodation) have been–and will continue to be–offset. This means that–while we still encourage clients to go fully virtual to cut down on their meeting-associated emissions almost entirely–those opting for a hybrid event can still feel good knowing that any Impetus support staff attending the meeting in person is not contributing to the carbon footprint of the event.
In fact, we were recently promoted to the Aclymate Silver Tier for our efforts to date. Plus, we continue to be platinum-certified by the Green Business Benchmark (GBB), demonstrating our commitment to sustainable practices!
Phase 3 and beyond will involve calculating and offsetting the emissions associated with the actual meeting venues, any Impetus business trips for reasons other than attending live client meetings and events (e.g., conference attendance), and the small but non-negligible emissions associated with our online portals. Stay tuned for more updates!
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here’s another one to keep in…
Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care…
Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform…
In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal…
Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive…
Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the…
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.
Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #8. The Ease and Effectiveness of Sharing Knowledge and Data…
Here’s another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #7. Everyone Gets a Say Another top benefit for the…
We’re breaking down the benefits of virtual advisory boards, and how they are superior when compared to in-person and hybrid advisory boards. #6. Far Superior Convenience Most KOLs have extremely…


